U.S. markets open in 2 hours 52 minutes

Molecular Partners AG (MOLN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
19.38+0.17 (+0.88%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close19.21
Open19.49
Bid19.44 x 800
Ask19.53 x 800
Day's Range19.37 - 19.58
52 Week Range18.00 - 21.33
Volume911
Avg. Volume34,444
Market Cap568.66M
Beta (5Y Monthly)0.67
PE Ratio (TTM)N/A
EPS (TTM)-2.66
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Molecular Partners AG
    Daily – Vickers Top Buyers & Sellers for 06/30/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • GlobeNewswire

    Molecular Partners to Present at Upcoming Healthcare Investor Conferences

    ZURICH-SCHLIEREN, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will present at two upcoming virtual healthcare investor events in September 2021. Conference Presentation Details: Event: Morgan Stanley 19th Annual Global Healthcare ConferenceDate/Time: Frida

  • GlobeNewswire

    Molecular Partners Reports Corporate Highlights and Key Financials for H1 2021

    -- Significant progress in COVID-19 trials, including positive results from healthy subjects and COVID-19 patients, supporting the launch of ongoing late-stage trials EMPATHY and ACTIV-3 Research & Development: Initiated two global Phase 2 and 3 trials of ensovibep (MP0420), to explore safety and efficacy in ambulatory patients with COVID-19 (EMPATHY) in collaboration with Novartis, and hospitalized patients (ACTIV-3) sponsored by the National Institutes of Health (NIH)Received FDA Fast Track de

  • GlobeNewswire

    Molecular Partners to Regain Global Rights to Abicipar

    Global rights to registrational-stage ophthalmology drug return to Molecular PartnersImprovements in manufacturing and formulation have been made and tested in pre-clinical models with the potential to overcome inflammatory side effectsOngoing research discovery alliance with AbbVie in ophthalmology to continue ZURICH-SCHLIEREN, Switzerland, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LRMolecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech compan